Vertex Pharmaceuticals VRTX reported strong second-quarter results driven by the continued robust uptake of its cystic fibrosis triple-combination therapy, Trikafta/Kaftrio. Product revenue of $2.49 ...

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 6.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, ...

Vertex VRTX reported third-quarter results highlighted by strong uptake of its cystic fibrosis triple combination therapy, Trikafta/Kaftrio, in the United States and internationally. Quarterly product ...

-More than 1,200 children are newly eligible for a medicine that could treat the underlying cause of their disease- About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor ...

Vertex Pharmaceuticals Incorporated VRTX is scheduled to release fourth-quarter and full-year 2023 results on Feb 5, after market close. The company has an impressive earnings surprise history, ...

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...

Vertex's stock has risen 18% since last December, matching the SPY index, bolstered by promising Phase 2 data for VX-548 in diabetic peripheral neuropathy. Vertex is expanding into gene therapies and ...

Vertex Pharmaceuticals generates strong sales growth from Trikafta/Kaftrio, which still has more untapped potential. Occidental Petroleum's business benefited from rising oil prices, and its profits ...

WHO expands Essential Medicines List to include diabetes, obesity treatments, cystic fibrosis, and cancer drugs, urging ...